Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company dedicated to developing innovative treatments for challenging neurodegenerative and metabolic disorders, announced it has engaged Stocks.news through IR Agency LLC for investor relations and consulting services. The agreement, effective June 8, 2026, is for a six-month term and includes a fee of US$250,000. This move signals the company's intent to bolster its communication with the investment community as it advances its pipeline of drug candidates.
Under the agreement, IR Agency LLC will provide a range of services including company profile creation, media distribution, digital community development, news marketing, and lead generation campaigns. Quantum emphasized that IR Agency LLC is arm's-length to the company and holds no direct or indirect equity interest in its securities, ensuring an unbiased approach to investor outreach. The full press release is available at https://ibn.fm/iBZrw.
Quantum BioPharma is focused on building a portfolio of innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing its lead compound, Lucid-MS, a patented new chemical entity that has shown potential to prevent and reverse myelin degradation in preclinical models of multiple sclerosis. This mechanism targets the underlying cause of the disease, offering a novel therapeutic approach.
Additionally, Quantum has developed UNBUZZD(TM), a product aimed at addressing alcohol misuse, and has spun out its over-the-counter version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd(TM) until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Importantly, Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. More information about Unbuzzd can be found at https://www.unbuzzd.com.
The engagement of Stocks.news underscores Quantum's commitment to effectively communicate its progress and value proposition to potential investors. The company's newsroom, available at https://ibn.fm/QNTM, provides updates on its latest developments. For the investment community, this agreement may enhance transparency and access to information about Quantum's clinical and commercial milestones, potentially influencing investor sentiment and market perception. As Quantum continues to develop its pipeline, effective investor relations will be crucial in securing the capital needed to advance its therapies through clinical trials and toward commercialization.
